Treace Medical Concepts Inc (TMCI) Stock Forecast & Price Target
Treace Medical Concepts Inc · NASDAQ
$4.01-0.07 (-1.84%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Treace Medical Concepts Inc, 1 rate it Buy or better, 4 sit at Hold, and 1 rate it Sell or worse, a hold consensus. Targets span $4.00 to $7.00, a moderate spread. The average target of $5.50 sits 37% above the current $4.01. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.24 next quarter toward $-0.90 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Hold
Strong Buy00%
Buy117%
Hold467%
Sell117%
Strong Sell00%
Based on 6 analysts giving stock ratings to Treace Medical Concepts Inc.
As of Jul, 1 of 6 firms rate TMCI a Buy (4 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
TMCI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.24
Range $-0.24 – $-0.24 · 1 analysts · +8% YoY
Next period, 1 analysts expect Treace Medical Concepts Inc to earn $-0.24 a share (range $-0.24 – $-0.24), versus $-0.22 a year earlier. Full-year consensus is $-0.91, growing to $-0.90 the year after.
REVENUE · NEXT QUARTER
$47.8M
Range $47.2M – $48.3M · 1 analysts · -5% YoY
Revenue is expected to reach $47.8M (range $47.2M – $48.3M), -4.8% year-over-year. Full-year consensus is $206.3M, rising to $221.8M next year.
Top analysts covering Treace Medical Concepts Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TMCI.
#1
Ryan Zimmerman
BTIG
Hold
No targeton TMCI
Coverage
—
+ Follow
#2
LL
Lilia-Celine (Lily) Lozada
J.P. Morgan
Sell
$5.00+24.8% to target
Coverage
—
+ Follow
#3
Richard Newitter
Truist Securities
Hold
$4.00-0.1% to target
Coverage
—
+ Follow
#4
BH
Ben Haynor
Lake Street
Buy
$7.00+74.8% to target
Coverage
—
+ Follow
TMCI stock forecast FAQ
What is TMCI's average 12-month price target?+
The 2 analysts with a live target average $5.50 for Treace Medical Concepts Inc over the next 12 months, ranging from a $7.00 high to a $4.00 low.
Is TMCI stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 6 analyst ratings, 1 are Buy or Strong Buy, 4 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for TMCI?+
The Street-high target is $7.00 (Lake Street), and the Street-low is $4.00 (Truist Securities). The average of all 2 active targets is $5.50.
How many Wall Street analysts cover TMCI?+
6 analysts have an active rating on Treace Medical Concepts Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering TMCI?+
Among analysts who currently cover TMCI, Ryan Zimmerman of BTIG has the strongest overall Quantellect track record. Their current call is Hold.
What is Treace Medical Concepts Inc's projected EPS for next quarter?+
The consensus estimate is $-0.24 per share (range $-0.24 – $-0.24) across 1 analysts. Full-year EPS is projected at $-0.91, rising to $-0.90 the following year.
How much revenue is Treace Medical Concepts Inc expected to report next quarter?+
Consensus revenue is $47.8M (range $47.2M – $48.3M). Full-year revenue is projected at $206.3M, growing to $221.8M next year.
Have analysts been upgrading or downgrading TMCI lately?+
As of Jul, 1 of 6 firms rate TMCI a Buy (4 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TMCI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
